

## Author Index to Volume 12

- Aarnaes, S.L., 269  
Ackerman, V.P., 153S  
Adams, M.A., 181  
Agy, M.B., 303  
Ajello, L., 21  
Akalin, E., 185S  
Akhter, J., 291  
Aldridge, K.E., 1S, 45, 165, 221, 489  
Alexander, W., 123  
Allen, S.D., 413, 489  
Amsterdam, D., 157  
Anhalt, J.P., 463  
Arbo, A., 147S  
Armstrong, D., 517  
Aujard, Y., 87  
Ayers, L.W., 413  
  
Bale, M., 337  
Balentine, L.T., 189  
Balfour Jr., H.H., 288  
Balows, A., 289, 455, 525  
Bandelloni, R., 53S  
Barg, N.L., 357  
Barry, A.L., 81, 143, 279, 381, 385, 413, 495  
Bartlett, K.R., 437  
Baskerville, A.J., 65S  
Beam Jr., T., 157  
Bergstrom, R., 73  
Bermudez, L.M., 17S  
Bianchini, H.N., 45S  
Bindra, R., 315  
Bivins, B.A., 113  
Blumberg, D.A., 351  
Bodey, G.P., 209S  
Bostick, C.C., 287  
Brackman, M.A., 449  
Brion, F., 87  
Burdick, C., 189  
  
Cabezudo, I., 337  
Calikoglu, A.S., 185S  
Canawati, H.N., 33  
Canupp, K.C., 433  
Carlson, L.C., 303  
Cassell, G.H., 193, 433  
Castrillon de P., L., 51S  
Chaffin, D.O., 445  
Chan, J., 193  
Chang, S.T., 175S  
Chan-Thim, J., 473  
Chapis, C., 129  
Chen, C.-M., 179S  
Cherry, J.D., 351  
Chin, N.-X., 283, 343, 477  
Chretien, P., 87  
Chu, M.-L., 179S  
Chung, H.Y., 175S  
Clark, N.C., 13  
Cleary, T., 193  
Cleri, D.J., 9  
Clynes, N., 257  
Collaborative Antimicrobial Susceptibility Testing Group, The, 413  
Congeni, B.L., 287  
  
Conville, P.S., 217, 309, 401  
Cooksey, R.C., 13  
Cordin, X., 139S  
Coyle, M.B., 303  
Crane, D., 288  
Criqui, C., 87  
Crots, L., 113  
Cunha, B.A., 291  
Curtis, S.E., 315  
  
Dahlgren, J., 215  
Dalton, M.T., 521  
D'Amato, R.F., 9  
Dascal, A., 473  
Dean, D., 133  
Debbia, E., 53S  
Degagne, P.A., 437, 83S  
de la Maza L.M., 269  
Dirksen, C.L., 288  
DiVincenzo, C.A., 13S  
Dubois, J., 89S  
Duffy, L.B., 433  
Dugger, K.O., 199  
Dulworth, J.K., 449  
Dupont, H.L., 139  
  
Eades, S.C., 57  
Ecevit, Z., 185S  
Edberg, S.C., 129  
Edelstein, M.A.C., 93S  
Edelstein, P.H., 93S  
Eliopoulos, G.M., 149, 481  
Elwing, H., 171  
Erickson, R.C., 235  
  
Faro, S., 189S  
Fath, J.J., 113  
Fedorko, D.P., 463  
Felmingham, D., 65S  
Fernandes, C.J., 153S  
Fernandez, A., 45S  
Ferraro, M.J., 481  
Ferrero, S.M., 45S  
Fikrig, E., 357  
Finegold, S.M., 117S  
Fiss, E.F., 211  
Folds, J.D., 319  
Forward, K.R., 205, 437  
Friis, H., 67  
Fuchs, P.C., 81, 413, 489  
  
Galgiani, J.N., 199  
Gallo, P., 129  
Gardiner, R.V., 271, 385  
Gaudet, E.A., 93S  
Gavan T.L., 413  
Gebbia, K., 221  
Gelfand, M.S., 421  
Gerarden, T., 1, 467  
Gerlach, E.H., 101, 413, 489  
Germer, J.J., 463  
Gibbons, A., 73  
Gibson, C.B., 235, 449  
Gleaves, C.A., 315  
Golper, T.A., 457  
Gomez, C., 51S  
  
Goodpasture, H.C., 101  
Gorzynski, E., 157  
Grabowski, M., 77S  
Gray, L.D., 275  
Griffis, J., 327  
Grogan, J.T., 421  
Grüneberg, R.N., 65S  
Gunel, M., 185S  
Gvazdinskas, L.C., 107, 253  
  
Haas, M.J., 421  
Haldane, D.J.M., 521  
Hall, N., 295  
Hammill, H.A., 189S  
Harrison, B.B., 107  
Hasegawa, H., 215S  
Helms, C., 295  
Henderberg, A., 1S, 221  
Herrmann, K.L., 333  
Hii, J., 517  
Hildebrand, A.R., 235, 449  
Hilliard, J.K., 333  
Hinthorn, D.R., 17  
Ho, D.H., 209S  
Hoban, D., 77, 83S  
Hochstein, L., 9  
Hoeprich, P.D., 17  
Hoffmann, P.F., 235  
Holland, M.D., 457  
Hollis, R., 295  
Holmes, G.P., 333  
Horiuchi, A., 215S  
Hörnsten, E.G., 171  
Horst, H.M., 113  
Houston, A., 1  
Hsu, C.-Y., 179S  
Huang, L.-M., 179S  
Hunt, T.L., 181  
Hursh, D.A., 315  
  
Icenogle, J., 197  
Ikemoto, H., 239S  
Ilstrup, D.M., 275  
Inderlied, C.B., 17S  
Ingaramo, R.A., 45S  
  
Jacobs, R.F., 93  
Jacoby, G.A., 481  
Jacqz-Aigrain, E., 87  
Janney, A., 221  
Jenkins, S.G., 51  
Johnson, J., 9  
Johnson, W., 295  
Joly, J.R., 89S, 295  
Jones, P.D., 235S  
Jones, R.N., 23, 25, 81, 101, 103S, 143, 271, 279, 363, 367, 381, 385, 413, 489, 495  
  
Kageyama, T., 215S  
Kanra, G., 185S  
Kapell, K., 87S  
Kasse, M.C., 87  
Kaufman, C., 45S  
Kawagoe, H., 215S  
Kazmierczak, A., 139S

- Kearns, G.L., 93  
 Keiser, J.F., 217, 309  
 Kenny, M.T., 449  
 Kernodle, D.S., 57  
 Kessler, H.A., 87S  
 Kiehn, T.E., 517  
 Kiley, M.P., 333  
 Kipp, J., 97S  
 Kitani, T., 215S  
 Klastersky, J., 165, 201S  
 Klimm, K., 481  
 Knapp, C.C., 511  
 Koss, J., 77S  
 Kuritza, A.P., 129  
  
 Labia, R., 139S  
 Lancero, M.G., 17S  
 Landry, M.L., 407  
 Lee, C.F., 315  
 Lee, C.-Y., 179S  
 Lee, J.H., 175S  
 Lee, M.-J., 179S  
 Lehman, S.M., 463  
 Lin, T.-Y., 179S  
 Lipper, S.L., 333  
 Lipson, S.M., 361  
 Lisker, A., 319  
 Liu, C., 17  
 Lundström, I., 171  
  
 Maccato, M., 189S  
 MacDonald, J., 521  
 MacLowry, J.D., 177  
 Magalhaes, M., 35S  
 Mahafzah, A.M., 407  
 Marriott, D., 235S  
 Martens, M.G., 189S  
 Martinez, O.V., 193  
 Masaoka, T., 215S  
 Massanari, R.M., 295  
 Mathew, A., 9  
 Mathew, T.K., 205  
 Mathewson, J.J., 139  
 Mathieu, H., 87  
 Matsen, J.M., 7S  
 mejia de R., G.I., 51S  
 Mendelman, P.M., 445  
 Mendelson, J., 473  
 Miller, P., 209S  
 Moellering Jr., R.C., 149, 481  
 Molinari, G., 53S  
 Montelli, A.C., 35S  
 Morahan, M., 473  
 Moyer, N., 295  
 Müller, S., 97S  
 Mumtaz, G., 65S  
 Munro, R., 159S  
  
 Nagai, K., 215S  
 Neihart, R.E., 17  
 Nelson, J.A., 107  
 Neu, H.C., 23, 103S, 107S, 109S, 119, 243, 249S, 257, 283, 343, 441, 477  
 Nevel, C.A., 211  
 Nichols, R.L., 195S  
 Nilsson, L.E., 171  
 Niu, W.-W., 243, 477  
  
 Notario, R., 45S  
 Novick Jr., W.J., 149  
  
 Obeid, F.N., 113  
 O'Hanley, P., 133  
 Ongsansoy, E.G., 205  
 Osborne, T.A., 287  
 Ostrawski, S., 291  
  
 Packer, R.R., 385  
 Paglia, P., 53S  
 Pai, S.D., 175S  
 Pant, C.R., 133  
 Paolasso, R., 45S  
 Papasian, C.J., 189  
 Parkhurst, G.W., 107  
 Pate, M.S., 433  
 Pechinot, A., 139S  
 Perez, S., 45S  
 Peter, K., 131S  
 Peterie, J.D., 101  
 Peterson, E.M., 269  
 Pfaller, M.A., 1, 295, 337, 413, 467, 489  
 Phillips, G., 429  
 Phillips, P., 429  
 Plorde, J.J., 303  
 Polsky, B., 517  
 Portnoy, J., 473  
 Porven, G., 45S  
  
 Qadri, S.G.M., 291  
 Qadri, S.M.H., 291  
  
 Reiszner, E., 149  
 Rice, D.H., 315  
 Riddle, G., 189S  
 Ridgway, G.L., 65S  
 Rimland, D., 123  
 Rinaldi, M.G., 429  
 Robbins, M.J., 65S  
 Rossolini, G.M., 57S  
 Rotstein, C., 157  
  
 Saha, G., 283  
 Sanders, C.V., 1S, 165, 221  
 Sanghrajka, M., 65S  
 Santos, J.I., 147S  
 Sarachian, B., 45S  
 Satta, G., 57S  
 Saubolle, M.A., 457  
 Sawai, T., 121S  
 Saxon, B., 7S  
 Schiro, D.D., 221  
 Schito, G.C., 53S  
 Schmitt, B.A., 107  
 Schonberger, L.B., 333  
 Scully, B.E., 257  
 Secmeer, G., 185S  
 Secor, S.L., 139  
 Segreti, J., 87S, 253  
 Sewell, D.L., 261, 457  
 Shah, P.M., 97S  
 Shatzer, K.L., 13S  
 Shimada, K., 171S  
 Siebor, E., 139S  
 Sierra-Madero, J., 511  
 Smith, D., 189S  
 Smith, T.F., 5, 275  
  
 Sonstein, S.A., 21S  
 Sorensen, V.J., 113  
 Speed, B.R., 235S  
 Staneck, J.L., 449  
 Starr, E., 211  
 Stein, D.K., 221S  
 Stevens, D.L., 73  
 Stewart, J.A., 333  
 Stille, W., 97S  
 Stratton, C.W., 29S, 57, 165  
 Strausbaugh, L.J., 261  
 Subbarao, E.K., 327  
 Sugar, A.L., 221S  
 Surmont, I., 265  
 Swenson, J.M., 13  
  
 Tarim, O., 185S  
 Telenti, A., 5  
 Telzak, E.E., 517  
 Thomson Jr., R.B., 287  
 Thornsberry, C., 13  
 Torney, H.L., 449  
 Torres, J.R., 41S  
 Trabulsi, L.R., 35S  
 Travis, L.B., 177  
 Trenholme, G.M., 87S, 107, 253  
 Truant, A.L., 211  
 Trujillo, H., 51S  
 Tsolakis, M., 211  
  
 Valentini, S., 57S  
 Vanbosterhaut, B., 265  
 Vandepitte, J., 265  
 Van der Auwera, P., 165S  
 Vandeven, J., 265  
 Venezio, F.R., 13S  
  
 Waites, K.B., 433  
 Wallis, C.K., 303  
 Waner, J.L., 327  
 Washington, J.A., 413, 511  
 Washton, H., 229S  
 Wasilauskas, B.L., 39  
 Wauters, G., 265  
 Weckbach, L.S., 449  
 Weeks, L.S., 29S, 57, 165  
 Wells, D.L., 333  
 Wellstood, S., 395  
 Wendt, S.E., 315  
 Wenzel, R.P., 1, 295, 337  
 Weselowski, V., 77S  
 Wey, S., 1  
 Wiedemann, B., 131S  
 Willey, S., 149  
 Willoughby, P.B., 319  
 Winsor Jr., D.K., 139  
 Witebsky, F.G., 217, 309, 401  
 Witwicki, E., 83S  
 Wood, C.A., 261  
 Wood, W.S., 429  
 Wright, D.N., 7S  
  
 Yamaguchi, A., 121S  
 Yasunaga, K., 215S  
 Yonezawa, T., 215S  
 Young, L.S., 17S  
 Yu, K.-W., 441  
 Yu, P.K.W., 463

## Subject Index to Volume 12

- A549 cell culture  
  adenovirus infection detected via, 407
- A16686  
  antibacterial activity of, 279
- Abbott kit  
  HIV-1 antigen detected via, 319
- Abcess  
  brain, *Mycoplasma hominis* associated with, 193  
  cutaneous, streptococcal, 189
- Abcess model  
  rat peritoneal, cefotaxime efficacy assessed via, 149
- Abdominal trauma  
  penetrating, antibiotic regimens against, 113
- Acinetobacter anitratus*  
  piperacillin/tazobactam against, 481
- Acinetobacter baumannii*  
  sulbactam/ $\beta$ -lactam antibiotics against, 165S
- Acinetobacter calcoaceticus*  
  lomefloxacin against, 45S  
  sulbactam/ampicillin against, 179S
- Acinetobacter* spp.  
  ampicillin resistance in, 249S  
  desacetylcephalotaxin against, 23, 119  
  lomefloxacin against, 1S, 77S, 221  
  MDL 19, 592 against, 441  
  sulbactam/cefoperazone against, 209S
- Acquired immune deficiency syndrome (AIDS)  
  cryptococcal meningitis in, fluconazole against, 235S  
  fungal infections associated with, 221S  
  mycobacteremia as common feature of, 303  
  *Mycobacterium avium* in, lomefloxacin against, 17S  
  mycoses associated with, fluconazole against, 239S  
  *Nocardia asteroides* pneumonia in, 517
- Aculeacin A  
  antifungal activity of, 1
- Acyclovir  
  in humans, peak serum levels achievable, 5
- AD169 strain  
  cytomegalovirus, antiviral activity against, 5
- Adenoclone enzyme immunoassay kit  
  adenovirus isolates identified via, 361, 407
- Adenosine triphosphate (ATP)  
  assay of based on ampicillin susceptibility tests, *Escherichia coli* spheroplast formation and, 171
- Adenoviruses  
  diagnosis of infection by, 407  
  identification of, 361  
  respiratory syncytial virus in conjunction with, 327
- Agar dilution screening  
  inhibitory activity of antibacterial drugs assessed via, 33, 39, 51  
  staphylococcal resistance to penicillinase-resistant penicillins assessed via, 385
- Agrobacterium radiobacter*  
  bacteremia, foreign body removal as therapy for, 351
- AIDS, See Acquired immune deficiency syndrome
- Amikacin  
  antibacterial activity of, 157
- Aminoglycosides  
  nephrotoxicity and ototoxicity of, 9
- Amoxicillin  
  antibacterial activity of, 57S, 65S
- amp D gene  
  inactivation of,  $\beta$ -lactamase induction and, 131S
- Amphotericin B  
  antibacterial activity of, 1  
  antifungal activity of, 235S  
  intolerance to, 17
- Amphotericin B methyl ester  
  against fungal infections, 17
- Ampicillin  
  antibacterial activity of, 9, 87, 93, 171  
  resistance to, 159S, 181, 249S, 283
- Ampicillin/sulbactam  
  antibacterial activity of, 9, 39, 117S, 421
- AMS-Vitek GNI card  
  gram-negative bacilli identified via, 211
- Antibiograms  
  of morphological variants of blood culture isolates, clinically significant differences in, 177
- Arthritis  
  septic, 189, 193
- Aspergillosis  
  azoles against, 221S  
  fluconazole against, 239S
- Aspergillus* spp.  
  fluconazole against, 239S  
  in immunocompromised hosts, 221S
- ATP, See Adenosine triphosphate
- Autobac 18 chamber cuvette  
  gram-negative bacilli identified via, 211
- Azlocillin  
  resistance to, 283
- Azole antifungal agents  
  activity of, 221S, 467
- Aztreonam  
  activity of not enhanced by blood product medium supplements, 149  
  lomefloxacin activity greater than, 221  
  resistance to, 283
- Bacillus cereus*  
  penicillinase, in teicoplanin bioassay, 449
- Bacillus* spp.  
  ramoplanin against, 279
- Bacillus subtilis*  
  ATCC 6633, as bioassay organism, 235  
  in teicoplanin bioassay, 449
- Bactec blood cultures  
  evaluation of, 303  
  microbial dialysates inoculated into, 457  
  mycobacterial DNA probe analysis and, 309  
  mycobacterial inter-bottle transfer in, 401  
  *Mycobacterium avium* complex identified in, 217  
  *Staphylococcus aureus* identified in, 205
- Bacteremia  
  *Agrobacterium radiobacter*, 351  
  CDC Group Ve-2, 351  
  gram-negative, cefotaxime against, 107  
  *Mycobacterium avium* complex, 309
- Bacteroides bivius*  
  cefotaxime-desacetylcefotaxime against, 45  
  metronidazole/gentamicin against, 189S  
  sulbactam/ampicillin against, 189S
- Bacteroides capillosus*  
  cefotaxime-desacetylcefotaxime against, 45
- Bacteroides disiens*  
  cefotaxime-desacetylcefotaxime against, 45
- Bacteroides distasonis*  
  cefotaxime against, 39  
  cefotaxime-desacetylcefotaxime against, 39
- Bacteroides fragilis*  
  antibiotics against, 195S  
  cefoperazone against, 421  
  cefoperazone/sulbactam against, 421  
  cefotaxime against, 45, 165  
  cefotaxime-desacetylcefotaxime against, 23, 33, 39, 45, 120, 165  
  cefotetan against, 39  
  cefoxime against, 33  
  cefoxitin against, 33, 39  
  cephalosporinases produced by, cefmetazole inhibition of, 367  
  desacetylcefotaxime against, 33, 45, 165  
  lomefloxacin against, 103S  
  piperacillin/tazobactam against, 481, 489  
  resistance in, 117S, 159S, 249S  
  sulbactam/ampicillin against, 179S
- Bacteroides melaninogenicus*  
  cefotaxime-desacetylcefotaxime against, 45  
   $\beta$ -lactamase production in, penicillin inactivated by, 477
- Bacteroides ovatus*  
  cefotaxime-desacetylcefotaxime against, 33  
  cefoxitin against, 33
- Bacteroides* spp.  
  cefoperazone against, 421  
  cefoperazone/sulbactam against, 421  
  cefotaxime-desacetylcefotaxime against, 33



- cefoxitin against, 33  
 lomefloxacin against, 65S  
 resistance in, 159S, 249S  
*Bacteroides thetaiotamicron*  
 cefotaxime against, 39  
 cefotaxime-desacetylcefotaxime against, 33, 39, 120  
 cefoxitin against, 33  
*Bacteroides vulgatus*  
 cefotaxime-desacetylcefotaxime against, 33  
 cefoxitin against, 33  
*Blastocystis hominis*  
 detection of in diarrheal stools, 291  
 BMY 28142  
 against respiratory infections, 257  
 Bone marrow transplant  
 allogeneic, invasive hyalohyphomycosis associated with, 429  
 Brain abscesses  
*Mycoplasma hominis* associated with, 193  
*Branhamella catarrhalis*  
 cefmetazole against, 367  
 cefotaxime against, 165  
 identification of, 130  
 lomefloxacin against, 45S, 221, 437  
 novobiocin against, 363  
 SM-7338 against, 271  
 Brazilian purpuric fever  
 PBP profiles of *Haemophilus* spp. associated with, 445  
 Broth microdilution method  
*Bacteroides* susceptibility assessed via, 421  
 cefotaxime activity assessed via, 81  
 cefotaxime-desacetylcefotaxime activity assessed via, 81  
 cefuroxime activity assessed via, 517  
 desacetylcefotaxime activity assessed via, 81  
 in vitro susceptibility testing using, 1  
 lomefloxacin activity assessed via, 1S  
 quality control limits for, 413  
 SM-7338 stability assessed via, 271  
 staphylococcal resistance to penicillinase-resistant penicillins assessed via, 385  
 terconazole activity assessed via, 467  
 B virus  
 cell culture contamination by, 333  
*Campylobacter jejuni*  
 lomefloxacin against, 65S  
*Campylobacter pylori*  
 lomefloxacin against, 35S  
 Cancer patients  
 infections in, sulbactam/cefoperazone against, 209S  
*Candida albicans*  
 identification of, 521  
 nosocomial isolates of, antifungal agents against, 1  
 terconazole against, 467  
*Candida guilliermondii*  
 nosocomial isolates of, antifungal agents against, 1  
*Candida krusei*  
 nosocomial isolates of, antifungal agents against, 1  
*Candida lusitanae*  
 nosocomial isolates of, antifungal agents against, 1  
*Candida parapsilosis*  
 nosocomial isolates of, antifungal agents against, 1  
 terconazole against, 467  
*Candida rugosa*  
 nosocomial isolates of, antifungal agents against, 1  
*Candida* spp.  
 fluconazole against, 239S  
 in immunocompromised hosts, 221S  
*Candida tropicalis*  
 identification of, 521  
 nosocomial isolates of, antifungal agents against, 1  
 terconazole against, 467  
 Candidiasis  
 fluconazole against, 229S  
 mucocutaneous, in AIDS, 221S  
 Carbohydrate fermentation testing  
 gonococci identified via, 129  
 Carumonam  
 resistance to, 283  
 Catheterization  
 urinary, coagulase-negative staphylococci associated with infection associated with, 123  
 CDC Group Ve-2 bacteremia  
 antibiotic therapy against, 351  
 CDC reagent  
 adenovirus infection detected via, 407  
 Cefazolin  
 in teicoplanin bioassay, 449  
 Cefepime  
 antibacterial activity of, 343  
 against respiratory infections, 257  
 Cefmetazole  
 antibacterial activity of, 367  
 Cefoperazone  
 antibacterial activity of, 143, 209S, 421  
 metabolism of, 25  
 resistance to, 283  
 Cefoperazone/sulbactam  
 antibacterial activity of, 250S, 421  
 Ceforoxime  
 antibacterial activity of, 517  
 Cefotaxime  
 antibacterial activity of, 33, 35S, 45, 57, 67, 81, 87, 93, 101, 107, 119, 149, 165, 221, 337  
 resistance to, 283  
 Cefotaxime-desacetylcefotaxime  
 antibacterial activity of, 23, 33, 39, 51, 57, 67, 73, 81, 87, '65  
 Cefotetan  
 antibacterial activity of, 39  
 Cefotiam  
 activity of not enhanced by blood product medium supplements, 149  
 Cefoxitin  
 antibacterial activity of, 33, 39, 117S, 367  
 against penetrating abdominal trauma, 113  
 resistance to, 153S, 249S  
 Cefpirome  
 antibacterial activity of, 337, 343  
 Ceftazidime  
 antibacterial activity of, 143, 157, 221, 243, 337, 343, 489  
 resistance to, 283  
 in teicoplanin bioassay, 449  
 Ceftizoxime  
 antibacterial activity of, 39  
 resistance to, 283  
 Ceftriaxone  
 metabolism of, 25  
 resistance to, 283  
 in teicoplanin bioassay, 449  
 Cefuroxime  
 antibacterial activity of, 65S  
 in teicoplanin bioassay, 449  
 Cell culture  
 respiratory syncytial virus identified via, 327  
 Cellulitis  
 streptococcal, 357  
 Centrifugation culture  
 adenoviral isolates detected via, 407  
 herpes simplex virus detected via, 315  
 Centrifugation-Oxoid system  
 for microbial detection in dialysates, 457  
 Cephalixin  
 resistance to, 181  
 Cephaloglycin  
 metabolism of, 25  
 Cephalosporinases  
 cefmetazole inhibition and, 367  
 $\beta$ -lactamase inhibition and, 121S, 249S  
 Cephalothin  
 antibacterial activity of, 119  
 metabolism of, 25  
 Cephamycins  
 antibacterial activity of, 367  
 Cephaphirin  
 antibacterial activity of, 119  
 metabolism of, 25  
 CGP 31608  
 resistance to, 283  
 Chemiluminescence assay  
 luminol-enhanced, sulbactam activity assessed via, 139S, 147S  
 Children  
 bacterial infections in, drug therapy for, 93  
*Chlamydia trachomatis*  
 in conjunctival specimens, identification of, 133  
 lomefloxacin against, 65S, 83S, 87S, 103S  
 Chloramphenicol  
 antibacterial activity of, 39, 117S  
 metabolism of, 25  
 Chloramphenicol succinate  
 antibacterial activity of, 93  
 Cinoxacin  
 metabolism of, 25  
 Ciprofloxacin  
 antibacterial activity of, 17S, 29S, 65S, 83S, 87S, 93S, 243, 253, 433  
*Citrobacter freundii*  
 cephalosporinase, 121S, 249S

- Citrobacter* spp.  
lomefloxacin against, 51S, 181
- Clavanulate  
antibacterial activity of, 511  
resistance to, 283
- Clindamycin  
antibacterial activity of, 39, 117S  
against penetrating abdominal trauma, 113  
resistance to, 153S, 249S
- Clostridium difficile*  
colitis associated with, detection of, 291  
lomefloxacin against, 65S
- Clostridium perfringens*  
lomefloxacin against, 65S
- Clostridium* spp.  
resistance in, 117S, 159S, 249S
- Clotrimazole  
antibacterial activity of, 467
- CMV, see Cytomegalovirus
- Coccidioides immitis*  
fungal infections caused by, treatment of, 17
- Coccidioidomycosis  
in AIDS, 221S
- Colitis  
antibiotic-associated, detection of, 291
- Combination antibiotic therapy  
against penetrating abdominal trauma, 113
- Corynebacterium jeikeium*  
lomefloxacin against, 13S  
prosthetic valve endocarditis, diptheroid, 265  
ramoplanin against, 279
- Cotrimoxazole  
antibacterial activity of, 57S, 201S
- Coulter kit  
HIV-1 antigen detected via, 319
- Cryptococcosis  
azoles against, 221S  
fluconazole against, 239S
- Cryptococcus neoformans*  
fluconazole against, 239S
- CS-1170  
antibacterial activity of, 367
- Cystic fibrosis  
*Pseudomonas* isolates from patients with, 343
- Cytocholasin B  
polymorphonuclear leukocyte activity measurement and, 199
- Cytomegalovirus (CMV)  
antiviral activity against, 5  
detection of, correlation of urine pH with, 275  
respiratory syncytial virus identified in conjunction with, 327
- Cytopathic effect  
adenovirus associated, 361
- Cytotoxic assay  
for detection of antibiotic associated colitis, 291
- Desacetylcefotaxime  
antibacterial activity of, 33, 39, 45, 67, 81, 87, 93, 119, 143, 165  
metabolism of, chemotherapy and, 25
- Desacetylcephalothin  
antibacterial activity of, 119
- DHPG, see Ganciclovir
- Diabetes mellitus  
foot ulcers in, bacterial infection associated, 33
- Dilution susceptibility testing  
of penicillinase-resistant penicillin isolates, 385  
of piperacillin/tazobactam, 495
- Diphtheroids  
Group JK, prosthetic valve endocarditis due to, 265
- Direct immunofluorescent antibody staining  
bacteria in conjunctival specimens identified via, 133  
herpes simplex virus identified via, 315
- Disk diffusion testing  
cefotaxime activity assessed via, 81  
cefotaxime-desacetylcefotaxime activity assessed via, 23, 67, 73, 81  
cefuroxime assessed via, 517  
SM-7338 stability assessed via, 271  
staphylococcal resistance to penicillinase-resistant penicillins detected via, 381, 385
- DNA gyrase  
in bacterial resistance, 109S, 249S
- DNA hybridization studies  
of nucleotide sequence homologous to to Tn1545 transposon, 13
- DNA probes  
bacteria in conjunctival specimens identified via, 133  
mycobacterial analysis via, 309  
technology and medical applications of, 525
- Doxycycline  
antibacterial activity of, 87S
- Dupont kit  
HIV-1 antigen detected via, 319
- E-1040  
antibacterial activity of, 343
- Echinocandin B  
LY121019 as novel analog of, 1
- Echoviruses  
respiratory syncytial virus identified in conjunction with, 327
- Empyema  
streptococcal, 189
- Endocarditis  
combination therapy against, 9  
native valve, staphylococcal, 261  
prosthetic valve, *Corynebacterium* associated, 265  
sulbactam/ampicillin against, 179S
- Endometritis, post-Cesarean section  
metronidazole/gentamicin against, 189S, 250S  
sulbactam/ampicillin against, 189S, 250S
- Enteritis  
lomefloxacin against, 181
- Enterobacter cloacae*  
cefotaxime-desacetylcefotaxime against, 73  
sulbactam/ampicillin against, 179S
- sulbactam/ $\beta$ -lactam antibiotics against, 165S
- Enterobacteriaceae*  
cefepime against, 257  
cefotaxime-desacetylcefotaxime against, 25, 120  
cefmetazole against, 367  
cefotaxime against, 165  
lomefloxacin against, 1S, 7S, 17S, 35S, 41S, 45S, 51S, 52S, 57S, 65S, 77S, 97S, 103S, 221  
MDL 19,592 against, 441  
piperacillin/tazobactam against, 481, 489  
QA-241 against, 243  
quinolones against, 201S  
sulbactam against, 139S  
ticarcillin/clavanulate against, 511
- Enterobacter* spp.  
lomefloxacin against, 51S
- Enterococci  
lomefloxacin against, 45S, 57S, 104S  
MDL 19,592 against, 441  
ramoplanin against, 279  
SM-7338 against, 271
- Enterococcus faecalis*  
ampicillin/sulbactam against, 9  
cefotaxime against, 149  
lomefloxacin against, 65S, 77S, 97S  
metronidazole/gentamicin against, 189S  
sulbactam/ampicillin against, 189S
- Enterococcus faecium*  
ampicillin/sulbactam against, 9
- Enterocolitis  
infective, sulbactam/ampicillin against, 179S
- Enzyme immunoassays  
for detection of HIV-1, 319
- Enzyme immunoassay transport medium  
special, replacement of by standard viral transport medium in Herp-check antigen detection test, 473
- Eosin-methylene blue agar  
*Salmonella* and *Shigella* recovery from, 463
- Erythromycin  
antibacterial activity of, 65S, 89S, 93S, 433  
resistance to, 153S
- Escherichia coli*  
ampicillin against, 87  
cefotaxime against, 101  
cefotaxime-desacetylcefotaxime against, 73  
cephalothin against, 119  
cephaphirin against, 119  
ciprofloxacin against, 29S  
lomefloxacin against, 29S, 51S, 57S, 65S, 97S, 181  
metronidazole/gentamicin against, 189S  
mezlocillin against, 157  
piperacillin/tazobactam against, 495  
polymorphonuclear leukocyte activity measurement and, 199  
QR-241 against, 243  
resistance in, 185S, 249S  
spheroplast formation in, ampicillin effect on, 171  
sulbactam against, 139S



- sulbactam/ampicillin against, 179S, 189S  
 sulbactam/ $\beta$ -lactam antibiotics against, 165S  
 ticarcillin-clavulanic acid against, 157
- FCE-22101  
   antibacterial activity of, 143
- Fleroxacin  
   antibacterial activity of, 143, 221
- Fluconazole  
   antifungal activity of, 229S, 235S, 239S, 250S
- Flucytosine  
   antifungal activity of, 235S
- 5-Fluorocytosine  
   antibacterial activity of, 1
- Fluoroquinolones  
   resistance to, 109S
- Fosfomycin  
   antibacterial activity of, 367
- Fungus ball formation  
   in preformed pulmonary cavity, as human mycosis, 429
- Fungal infections  
   fluconazole against, 229S  
   in immunocompromised hosts, treatment of, 221S
- Fungemia  
   fluconazole against, 239S
- Fusarium* spp.  
   in immunocompromised hosts, 221S
- Fusobacterium* spp.  
   resistance in, 117S, 249S
- Ganciclovir (DHDPG)  
   in humans, peak serum levels achievable in, 5
- Gastroenteritis  
   sulbactam/ampicillin against, 175S
- Genitourinary tract  
   manipulations of, sepsis following, 193
- Gen-Probe Rapid Diagnostic System  
   for *Mycobacterium avium* complex, 217, 309
- Gentamicin  
   antibacterial activity of, 35S, 51, 157, 221, 243  
   against penetrating abdominal trauma, 113  
   resistance to, 153S
- Germ-tube test  
   *Candida albicans* identified via, 521
- Giardia lamblia*  
   detection of in diarrheal stools, 291
- Gonococci  
   identification of, 129  
   lomefloxacin against, 89S  
   piperacillin/tazobactam against, 495
- Gonorrhea  
   identification of, 129
- Granulocytopenia  
   bacterial infections in, treatment of, 201S
- Haemophilus aegyptus*  
   PBP analysis of, 445
- Haemophilus ducreyi*  
   lomefloxacin against, 83S, 103S
- Haemophilus influenzae*  
   cefmetazole against, 367  
   cefotaxime against, 165  
   cefotaxime-desacetylcefotaxime against, 120  
   lomefloxacin against, 45S, 89S, 104S, 221, 437  
   novobiocin against, 363  
   PBP analysis of, 445  
   piperacillin/tazobactam against, 495  
   QR-241 against, 243  
   sulbactam/ampicillin against, 179S  
   sulbactam/ $\beta$ -lactam antibiotics against, 165S
- Haemophilus* spp.  
   lomefloxacin against, 65S
- HEK cell culture  
   adenovirus infection detected via, 407
- Hematologic diseases  
   infections in, sulbactam/cefoperazone against, 215S
- Hemorrhage  
   intracerebral, varicella associated, 357
- HEp-2 cell culture  
   adenovirus infection detected via, 407
- Herpcheck antigen detection test  
   herpes simplex virus detected via, 473
- Herpes simplex virus (HSV)  
   characterization of, 197  
   detection of, 315, 473  
   monoclonal antibody typing reagents for, 269  
   respiratory syncytial virus identified in conjunction with, 327
- Herpesvirus simiae*  
   cell culture contamination by, 333
- Histoplasmosis  
   in AIDS, 221S  
   disseminated progressive, amphotericin B methyl ester against, 17
- HIV, *See* Human immunodeficiency virus
- HRE-664  
   antibacterial activity of, 143
- HSV, *See* Herpes simplex virus
- Human immunodeficiency virus (HIV)  
   detection of, 319  
   as underlying risk factor, cefepime therapy for respiratory infections and, 257
- Hyalohyphomycosis  
   invasive, of great toe, 429
- Hydrogen assay  
   molecular, based on ampicillin susceptibility tests, *Escherichia coli* spheroplast formation and, 171
- Imipenem  
   antibacterial activity of, 117S, 143, 221, 243, 271, 337, 489, 421  
   metabolism of, 25  
   resistance to, 283
- Immunocompromised patients  
   cryptococcal infections in, fluconazole against, 250S  
   fungal infections in, treatment of, 221S
- Immunofluorescence  
   adenovirus infection detected via, 407  
   respiratory syncytial virus identified via, 327
- Influenza  
   respiratory syncytial virus identified in conjunction with, 327
- Intrathoracic infection  
   sulbactam/ampicillin against, 185S
- Isolator/BACTEC 12B blood culture medium  
   evaluation of, 303
- Isolator/Middlebrook agar blood culture medium  
   evaluation of, 303
- IsoVitaleX supplement  
   SM-7338 stability in, 271
- Ketoconazole  
   antibacterial activity of, 1
- Klebsiella oxytoca*  
   mezlocillin against, 157  
   piperacillin against, 157  
   ticarcillin against, 157
- Klebsiella pneumoniae*  
   cefotaxime against, 101  
   cefotaxime-desacetylcefotaxime against, 73  
   cephalothin against, 119  
   cephapirin against, 119  
   ciprofloxacin against, 29S  
   lomefloxacin against, 29S
- Klebsiella* spp.  
   lomefloxacin against, 51S  
   resistance in, 153S, 249S
- $\beta$ -Lactamase  
   Class I, mutants derepressed for, 511  
   enterococcal production of, ampicillin/sulbactam against, 9  
   induction of, in gram-negative bacteria, 131S  
   inhibitors, antibacterial activity of, 283, 477, 481, 495  
   inhibitors, resistance and, 109S, 121S, 153S, 249S  
   staphylococcal, production of, 57
- $\beta$ -Lactam  
   antibacterial activity of, 57S, 165S, 143  
   resistance to, 109S  
   teicoplanin bioassay in presence of, 235, 449
- Lactose peptone broth  
   *Escherichia coli* in, 171
- Latex agglutination test  
   antibiotic-associated colitis detected via, 291  
   rotavirus detected in stool specimens via, 139  
   *Salmonella* detected via, 463  
   *Shigella* detected via, 463
- Legionella bozemanii*  
   ciprofloxacin against, 93S  
   erythromycin against, 93S  
   lomefloxacin against, 93S
- Legionella dumoffi*  
   ciprofloxacin against, 93S  
   erythromycin against, 93S

- lomefloxacin against, 89S, 93S
- Legionella hackeliae*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 93S
- Legionella longbeachae*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 93S
- Legionella maceachernii*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 93S
- Legionella micdadei*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 93S
- Legionella pneumophila*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 89S, 93S  
 serogroup 1, epidemiology of, 295
- Legionella* spp.  
 lomefloxacin against, 45S, 89S, 93S, 103S, 104S
- Legionella wadsworthii*  
 ciprofloxacin against, 93S  
 erythromycin against, 93S  
 lomefloxacin against, 93S
- Leukopenia  
 sulfadiazene-associated, 517
- Lincnoids  
 resistance to, 109S
- Listeria monocytogenes*  
 MDL 19,592 against, 441  
 ramoplanin against, 279
- Listeria* spp.  
 lomefloxacin against, 77S
- Lomefloxacin  
 antibacterial activity of, 1S, 7S, 13S, 17S, 21S, 29S, 35S, 41S, 45S, 51S, 77S, 83S, 87S, 89S, 93S, 97S, 103S, 221, 433, 437  
 multiple doses of, safety and tolerance of, 181  
 postantibiotic effect of, 52S, 57S, 65S
- Lung disease  
 chronic, cefipime against, 257
- LY121019  
 antibacterial activity of, 1
- Lysostaphin susceptibility test  
*Staphylococcus aureus* identified via, 205
- M7H11/BHI biphasic medium  
 evaluation of, 303
- Macrolides  
 resistance to, 109S
- MDL 19,592  
 antibacterial activity and  $\beta$ -lactamase stability of, 441
- MDL62198  
 antibacterial activity of, 279
- Meningitis  
 bacterial, drug therapy against, 93  
 cryptococcal, fluconazole against, 229S, 235S
- Meningococci  
 cefotaxime-desacetylcefotaxime against, 120
- Meniscal tear  
 acute, as predisposing factor for septic arthritis, 189
- Meritec-Rotavirus assay  
 rotavirus detected in stool specimens via, 139
- 4-Methylumbelliferyl-*N*-acetyl- $\beta$ -galactosaminide  
*Candida albicans* identification via, 521
- Metronidazole  
 antibacterial activity of, 39, 117S, 159S, 421  
 metabolism of, 25
- Metranidazole/gentamicin  
 antibacterial activity of, 189S, 250S
- Mezlocillin  
 antibacterial activity of, 157  
 resistance to, 283  
 in teicoplanin bioassay, 449
- Miconazole  
 antibacterial activity of, 467
- Microscan Combo Plus Panel  
 gram-negative bacilli identified via, 211
- MICs, see Minimum inhibitory concentrations
- Minimum inhibitory concentrations (MICs)  
 for ampicillin, 159S, 171  
 for ampicillin/sulbactam, 9  
 for cefazolin, 57  
 for cefmetazole, 367  
 for cefoperazone, 421  
 for cefotaxime, 33, 51, 57, 81, 87, 93, 101, 107, 165, 337  
 for cefotaxime-desacetylcefotaxime, 33, 45, 81, 165  
 for cefoxitin, 159S, 489  
 for ceftazidime, 337  
 for ceftazidime, 337  
 for cefuroxime, 517  
 for ciprofloxacin, 29S, 93S, 433  
 for clindamycin, 159S  
 for desacetylcefotaxime, 57, 165  
 for erythromycin, 93S, 433  
 for gentamicin, 81  
 for imipenem, 337  
 lomefloxacin, 1S, 7S, 13S, 17S, 29S, 35S, 41S, 45S, 51S, 52S, 57S, 65S, 77S, 83S, 87S, 89S, 93S, 97S, 104S, 181, 221, 433, 437  
 for LY121019, 1  
 for lysostaphin, 205  
 for MDL 19,592, 441  
 for metronidazole, 159S  
 for minocycline, 253  
 for novobiocin, 363  
 for penicillin, 13  
 for piperacillin, 337, 489, 511  
 for piperacillin/tazobactam, 489, 495, 511  
 for QR-241, 243  
 quality control limits for broth microdilution testing and, 413  
 for ramoplanin, 279  
 for rifampin, 253  
 for sulbactam, 139S  
 for sulbactam/ampicillin, 159S  
 for tazobactam, 495, 511  
 for teicoplanin, 385  
 for terconazole, 467  
 for tobramycin, 81, 337
- Minocycline  
 antistaphylococcal activity of, 253
- Miokamycin  
 antibacterial activity of, 57S
- Monoclonal antibodies  
 to early and late antigens of cytomegalovirus, 5
- Monoclonal antibody typing reagents  
 fluorescent, for identification of adenoviral isolates, 407  
 for herpes simplex virus, 269, 315  
*Legionella pneumophila* serogroup 1 epidemiology studied via, 295
- Moraxella catarrhalis*  
 SM-7338 against, 271
- Morganella morganii*  
 cefotaxime-desacetylcefotaxime against, 119  
 piperacillin/tazobactam against, 495
- Moxalactam  
 in vitro activity of not augmented by serum, 149
- MRC-5 cell culture  
 adenovirus infection detected via, 407
- MRS test  
 sensitivity of to staphylococci, evaluation of, 395
- Mucormycosis  
 fluconazole against, 239S
- Mueller-Hinton agar  
 sheep blood added to, effect of on cephalosporin antibacterial activity, 149
- Mueller-Hinton II agar  
 in teicoplanin bioassay medium, 235
- Mupirocin  
 antibacterial activity of, 279
- Mycobacterium avium*  
 detection of, 309  
 inter-bottle transfer of, 401  
 lomefloxacin against, 17S  
 mycobacteremia associated with, 303  
 simultaneous infection with *Mycobacterium intracellulare* in AIDS patient, 217
- Mycobacterium fortuitum*  
 inter-bottle transfer of, 402
- Mycobacterium haemophilum*  
 mycobacteremia associated with, 303
- Mycobacterium intracellulare*  
 inter-bottle transfer of, 402  
 simultaneous infection with *Mycobacterium avium* in AIDS patient, 217
- Mycobacterium* spp.  
 lomefloxacin against, 45S
- Mycobacterium tuberculosis*  
 detection of, 309  
 inter-bottle transfer of, 401  
 mycobacteremia associated with, 303
- Mycoplasma hominis*  
 lomefloxacin against, 65S, 83S



- sepsis caused by, in multiple trauma cases, 193
- Mycoplasma pneumoniae*  
ciprofloxacin against, 433  
erythromycin against, 433  
lomefloxacin against, 433
- Mycoplasma* spp.  
metronidazole/gentamicin against, 189S  
sulbactam/ampicillin against, 189S
- Mycoses  
deep, fluconazole against, 239S  
as public health problem, 21  
systemic, diagnosis and therapy of, 455
- Nafcillin  
in teicoplanin bioassay, 449
- Nalidixic acid  
metabolism of, 25
- Nasopharyngeal specimens  
yielding respiratory syncytial virus, multiple viral agents in, 327
- Neisseria flavescens*  
identification of, 130
- Neisseria gonorrhoeae*  
identification of, 129  
lomefloxacin against, 35S, 45S, 83S, 103S, 221  
piperacillin/tazobactam against, 495  
QR-241 against, 243  
SM-7338 against, 271  
sulbactam/ $\beta$ -lactam antibiotics against, 165S
- Neisseria lactamica*  
identification of, 129, 130
- Neisseria meningitidis*  
identification of, 130  
piperacillin/tazobactam against, 495
- Neisseria sicca*  
identification of, 130
- Neisseria* spp.  
cefmetazole against, 367  
lomefloxacin against, 65S, 104S  
novobiocin against, 363  
SM-7338 against, 271
- Neisseria subflava*  
identification of, 130
- Neonates  
bacterial infections in, drug therapy for, 87, 93
- Netilmicin  
antibacterial activity of, 57S, 210S
- Neutropenia  
bacterial infections in, treatment of, 201S  
gram-positive bacteria associated with, 143
- Neutrophils  
killing of single microorganisms by, measurement of, 199
- NIH-ELISA assay, rotavirus detected in stool specimens via, 139
- Nocardia asteroides*  
pneumonia, cefuroxime against, 517
- Norfloxacin  
antibacterial activity of, 35S, 52S, 57S, 87S, 221
- Novobiocin  
antibacterial activity of, 363
- NY-198  
antibacterial activity of, 1S, 7S, 21S, 29S, 41S, 45S, 87S, 89S, 93S, 97S, 103S, 221, 437
- Ofloxacin  
antibacterial activity of, 52S, 65S, 221, 243
- ORTHOProbe DNA probe test  
gonococci identified via, 129
- Osteoarthritis  
as predisposing factor for septic arthritis, 189
- Osteomyelitis  
vertebral, staphylococcal, 261
- Otitis media  
sulbactam/ampicillin against, 179S
- Oxoid system  
for microbial detection in dialysates, 457
- Oxytetracycline  
antibacterial activity of, 65S
- p24 antigen  
HIV-1, detection of, 319
- Papillomaviruses  
characterization of, 197
- Parainfluenza viruses  
respiratory syncytial virus identified in conjunction with, 327
- PBP analysis  
*Haemophilus* strain differentiation via, 445
- Pediatric infections  
sulbactam/ampicillin against, 179S, 185S
- Pelvic inflammatory disease  
*Mycoplasma hominis* associated with, 193
- Pelvic trauma  
sepsis following, 193
- Penicillin  
antibacterial activity of, 23, 157  
 $\beta$ -lactamase inactivation of, 477  
PBP analysis and, 445  
resistance to, 13, 381, 385
- Penicillinase  
 $\beta$ -lactamase inhibition and, 121S  
resistance to, 381, 385
- Penicillin G  
against enterococci, 9
- Peptostreptococcus* spp.  
lomefloxacin against, 65S  
sulbactam/ampicillin against, 179S
- Peritoneal dialysis  
continuous ambulatory, microbial detection in effluents from, 457
- Peritonitis  
sulbactam/ampicillin against, 179S
- Phosphonoformic acid  
in humans, peak serum levels achievable in, 5
- Piperacillin  
antibacterial activity of, 117S, 157, 337, 481, 495  
resistance to, 249S, 283, 477
- Piperacillin/tazobactam  
antibacterial activity of, 481, 489, 495, 511
- Plaque reduction assay  
antiviral activity against cytomegalovirus assessed via, 5
- Pneumococci  
resistance in, 13, 109S
- Pneumonia  
*Legionella pneumophila* serogroup 1, 295  
*Nocardia asteroides*, in AIDS, 517  
sulbactam/ampicillin against, 179S
- Pneumonitis  
hypersensitivity, as human mycosis, 429
- Polio viruses  
vaccine strain, respiratory syncytial virus identified in conjunction with, 327
- Polyclonal antibody reagents  
fluorescent, for identification of adenoviral isolates, 407
- Polymerase chain reaction  
amplified DNA probe, for identification of bacteria in conjunctival specimens, 133
- Polymorphonuclear leukocytes  
measurement of activity of, 199  
sulbactam effect on function of, 139S, 147S
- Primary rhesus monkey kidney cell cultures  
B virus contamination of, 333
- Prosthetic devices  
clinical infections in setting of, staphylococcal, 261
- Proteus mirabilis*  
lomefloxacin against, 51S  
mezlocillin against, 157  
sulbactam against, 139S  
sulbactam/ampicillin against, 179S  
ticarcillin against, 157  
ticarcillin/clavulanic acid against, 157  
trimethoprim resistance in, 153S
- Proteus* spp.  
lomefloxacin against, 35S, 51S, 181
- Proteus vulgaris*  
cefotaxime-desacetylcefotaxime against, 119  
piperacillin/tazobactam against, 495
- Providencia* spp.  
lomefloxacin against, 35S
- Providencia stuartii*  
piperacillin against, 157  
piperacillin/tazobactam against, 495  
ticarcillin against, 157
- Pseudomonas aeruginosa*  
amikacin against, 157  
cefepime against, 257  
cefoperazone against, 143  
cefotaxime against, 107, 337  
cefpirome against, 337  
ceftazidime against, 143, 157, 337  
ciprofloxacin against, 29S  
imipenem against, 143, 337  
lomefloxacin against, 1S, 7S, 13S, 17S, 29S, 35S, 41S, 45S, 52S, 57S, 65S, 77S, 97S, 221  
MDL 19,592 against, 441  
piperacillin against, 157, 337  
piperacillin/tazobactam against, 481  
QR-241 against, 243



- SM-7338 against, 271  
 sulbactam/ $\beta$ -lactam antibiotics against, 165S  
 ticarcillin against, 157  
 tobramycin against, 337
- Pseudomonas cepacia*  
 C-3 substituted cephalosporins against, 343  
 decacetylcephotaxime against, 23, 119  
 lomefloxacin against, 221
- Pseudomonas* spp.  
 cefotaxime/desacetylcefotaxime/amino-glycosides against, 51  
 lomefloxacin against, 17S, 21S, 45S, 51S, 104S  
 ticarcillin/clavanulate against, 511
- Pseudomonic acid  
 antibacterial activity of, 279
- Pyelonephritis  
*Mycoplasma hominis* associated with, 193
- Pyogenic infections  
 streptococcal, 189
- QA-241  
 in vitro activity of, comparative, 243
- Quinolones  
 fluorinated, metabolism of, 25
- Ramoplanin  
 antibacterial activity of, 279
- Resistance  
 bacterial, to antibiotics, 109S, 117S, 153S, 159S, 249S
- Respiratory syncytial virus (RSV)  
 nasopharyngeal specimens yielding, multiple viral agents in, 327
- Respiratory tract infections  
 cephalosporins against, 257  
 lomefloxacin against, 181  
 sulbactam/ampicillin against, 171S, 175S
- Restriction endonuclease analysis  
 of plasmid DNA, epidemiology of *Legionella pneumophila* serogroup 1 studied via, 295
- Rhinoviruses  
 respiratory syncytial virus identified in conjunction with, 327
- Rhizopus* spp.  
 in immunocompromised hosts, 221S
- Rifampin  
 antibacterial activity of, 65S, 89S, 253  
 metabolism of, 25  
 teicoplanin bioassay in presence of, 235, 449
- RO 23-9424  
 antibacterial activity of, 143
- Rotavirus  
 detection of, in stool specimens, 139, 291
- Rotazyme II assay, rotavirus detected in stool specimens via, 139
- RSV, *See* Respiratory syncytial virus
- Salmonella enteritidis*  
 cefotaxime against, 101  
 detection of in diarrheal stools, 291
- Salmonella* spp.  
 detection of, 463
- lomefloxacin against, 51S, 181  
 sulbactam/ampicillin against, 179S
- Salmonellosis  
 systemic, sulbactam/ampicillin against, 185S
- SC-47111  
 antibacterial activity of, 1S, 7S, 17S, 21S, 29S, 41S, 45S, 87S, 89S, 93S, 97S, 103S, 221, 437
- Scopulariopsis brevicaulis*  
 invasive hyalohyphomycosis caused by, 429
- Sepsis  
 intraabdominal, sulbactam/ampicillin against, 195S, 250S
- Septicemia  
 sulbactam/ampicillin against, 175S, 179S
- Serologic methods  
 gonococi identified via, 129
- Serratia marcescens*  
 cefotaxime against, 101  
 cefotaxime-desacetylcefotaxime against, 73  
 lomefloxacin against, 51S  
 sulbactam/ $\beta$ -lactam antibiotics against, 165S
- Serum bactericidal activity  
 as indicator of adequate antibiotic dosing, 101
- Sexually transmitted diseases  
 lomefloxacin against, 181
- Shell vial cell culture  
 assay based on, cytomegalovirus activity assessed via, 5, 275
- Shigella boydii*  
 detection of in diarrheal stools, 291
- Shigella sonnei*  
 sulbactam/ampicillin against, 179S
- Shigella* spp.  
 detection of, 463  
 lomefloxacin against, 51S, 181  
 piperacillin/tazobactam against, 495
- Skeletal system infection  
 sulbactam/ampicillin against, 185S
- Slime production  
 by coagulase-negative staphylococci, implication of as virulence factor in urinary tract infections, 123
- SM-7338  
 in susceptibility testing media, stability of, 271
- Soft tissue infections  
 sulbactam/ampicillin against, 179S, 185S
- Staphylococci  
 cefmetazole against, 367  
 cefotaxime-desacetylcefotaxime combination against, 25  
 clinically significant differences in antibiograms and, 177  
 contamination and, 205  
 identification of, 211, 395  
 lack of demographic characteristics or laboratory markers associated with, 123  
 lomefloxacin against, 7S, 17S, 21S, 35S, 45S, 51S, 52S, 57S, 89S, 97S, 104S  
 minocycline against, 253  
 novobiocin against, 363
- piperacillin/tazobactam against, 481, 495  
 resistance in, 109S, 381, 385  
 SM-7338 against, 271
- Staphylococcus aureus*  
 cefepime against, 257  
 cefmetazole against, 367  
 cefotaxime against, 57, 165  
 cefotaxime-desacetylcefotaxime against, 57, 73  
 cephalothin against, 119  
 cephalexin against, 119  
 ciprofloxacin against, 29S  
 desacetylcephalothin against, 119  
 fosfomycin against, 367  
 identification of, 205, 395  
 lomefloxacin against, 29S, 41S, 57S, 65S, 97S, 221  
 MDL 19,592 against, 441  
 minocycline against, 253  
 polymorphonuclear leukocyte activity measurement and, 199  
 QR-241 against, 243  
 resistance in, 385  
 sulbactam/ampicillin against, 179S  
 sulbactam/ $\beta$ -lactam antibiotics against, 165S  
 ticarcillin/clavulanic acid against, 157  
 vancomycin against, 157
- Staphylococcus capitis*  
 ramoplanin against, 279
- Staphylococcus epidermidis*  
 ciprofloxacin against, 29S  
 lomefloxacin against, 13S, 29S, 41S, 51S, 221  
 QR-241 against, 243  
 resistance in, 385  
 slime production by, 123  
 sulbactam/ampicillin against, 179S  
 ticarcillin/clavulanic acid against, 157  
 vancomycin against, 157
- Staphylococcus haemolyticus*  
 resistance in, 385, 385
- Staphylococcus saprophyticus*  
 not implicated as pathogen in urinary tract infections, 123  
 lomefloxacin against, 51S  
 ramoplanin against, 279
- Staphylococcus warneri*  
 native valve endocarditis due to, 261  
 vertebral osteomyelitis due to, 261
- Stool specimens  
 rotavirus detection in, 139  
*Salmonella* detection in, 463  
*Shigella* detection in, 463
- Streptococci  
 cefmetazole against, 367  
 cefotaxime-desacetylcefotaxime against, 120  
 lomefloxacin against, 21S, 35S, 41S, 45S, 51S, 77S  
 MDL 19,592 against, 441  
 neonatal infections caused by, 87  
 SM-7338 against, 271
- Streptococcus anginosus*  
 septic arthritis of knee caused by, 189
- Streptococcus faecalis*  
 QR-241 against, 243
- Streptococcus pneumoniae*

- cefepime against, 257  
 cefotaxime against, 165  
 cefotaxime-desacetylcefotaxime against, 120  
 ciprofloxacin against, 29S  
 lomefloxacin against, 29S, 65S  
 MDL 19,592 against, 441  
 Minnesota strain, multiresistant, 13  
*Streptococcus pyogenes*  
 ciprofloxacin against, 29S  
 lomefloxacin against, 29S  
 MDL 19,592 against, 441  
 sulbactam/ampicillin against, 179S  
 Sulbactam  
 antibacterial activity of, 165S  
 polymorphonuclear leukocyte function and, 147S  
 resistance to, 283  
 secondary modes of action for, 139S  
 Sulbactam/ampicillin  
 antibacterial activity of, 159S, 171S, 175S, 179S, 185S, 189S, 250S  
 polymorphonuclear leukocyte function and, 147S  
 resistance to, 153S  
 Sulbactam/cefoperazone  
 antibacterial activity of, 209S, 215S  
 Sulfadiazine  
 side effects of, 517  
 Sulfamethoxazole  
 antibacterial activity of, 65S  
 Sulfonamides  
 metabolism of, 25  
 resistance to, 109S  
 Sultamicillin  
 antibacterial activity of, 175S  
 Surgical wound infection  
 sulbactam/ampicillin against, 175S  
 Sykes Class I enzymes  
 produced by gram-negative bacteria, ticarcillin stable in presence of, 157  
 Tazobactam  
 antibacterial activity of, 481, 489, 495, 511  
 emergence of resistance prevented by, 477  
 Teicomycin  
 antibacterial activity of, 385  
 Teicoplanin  
 bioassay for, 235, 449  
 Terconazole  
 antibacterial activity of, 467  
 Tetracyclines  
 antibacterial activity of, 253  
 resistance to, 13, 109S  
 Theophylline  
 lomefloxacin administered with, 181  
 Thernonuclease test  
 rapid, *Staphylococcus aureus* identification via, 205  
 Thrombocytopenia  
 varicella associated intracerebral hemorrhage in absence of, 357  
 Thrombophlebitis  
 septic, in multiple trauma, 193  
 Ticarcillin  
 antibacterial activity of, 117S, 157  
 resistance to, 283  
 in teicoplanin bioassay, 449  
 Ticarcillin/clavanulate  
 antibacterial activity of, 421, 511  
 Ticarcillin/clavulanic acid  
 antibacterial activity of, 157, 221, 489  
 Time-kill studies  
 ampicillin/sulbactam activity assessed via, 9  
 Tissue culture passage  
 serial, for identification of bacteria in conjunctival specimens, 133  
 Tn1545 transposon  
 nucleotide sequence homologous to, 13  
 Tobramycin  
 antibacterial activity of, 51, 337, 343  
 Toenail infection  
 as human mycosis, 429  
 Tonsillitis  
 exudative, hemolytic streptococci in, 477  
 sulbactam/ampicillin against, 179S  
 Trachoma  
 epidemiology of, 133  
 Trichosporon spp.  
 in immunocompromised hosts, 221S  
 Trimethoprim  
 antibacterial activity of, 57S, 65S  
 resistance to, 109S, 153S  
 Trimethoprim/sulfamethoxazole  
 antibacterial activity of, 201S, 221, 253  
 Trough serum  
 bactericidal activity of, 101  
 Typhoid fever  
 sulbactam/ampicillin against, 175S  
*Ureaplasma* spp.  
 metronidazole/gentamicin against, 189S  
 sulbactam/ampicillin against, 189S  
*Ureaplasma urealyticum*  
 lomefloxacin against, 65S, 83S  
 Urinary tract infections  
 coagulase-negative staphylococci as cause of, 123  
 lomefloxacin against, 181  
 sulbactam/ampicillin against, 171S, 175S, 179S  
 Urine  
 pH, cytomegalovirus detection associated with, 275  
 Vaccines  
 technological advances in development of, 289  
 Vancomycin  
 antibacterial activity of, 157, 253, 265, 279, 385  
 Varicella zoster virus (VZV)  
 detection of, 287, 288  
 intracerebral hemorrhage associated with, 357  
*Vibrio* spp.  
 lomefloxacin against, 65S  
 Viral transport medium  
 standard, in Herpcheck antigen detection test, 473  
 Virogen Rotatest assay, rotavirus detected in stool specimens via, 139  
*Xanthomonas maltophilia*  
 resistance in, 283  
*Yersinia* spp.  
 lomefloxacin against, 181  
 YTR 830  
 antibacterial activity of, 481, 489, 495





